BTK Degrader Study Shows Promise for a New Class of CLL Therapies | Alexey Danilov MD PhD | #ASH2024

Duration of BTKi therapy correlates with time to next treatment in CLL | Kerry Rogers, MD | #ASH24

Benefits of Thorough Evaluations Before Starting AML Treatment | Samuel Yates, MD, MS | #ASH24

How Self-Rated Health Impacts Patient Outcomes| Nora Balas, PhD | #ASH24

Examining 3 Key Studies on Treatments for AML and ALL | Jayastu Senapati, MD, MBBS | #ASH24

Examining 3 Key Studies on Treatments for AML and ALL | Jayastu Senapati, MD, MBBS | #ASH24

Inpatient or Outpatient Consolidation Therapy: Which is Better?| Leora Boussi, MD | #ASH24

Racial Disparities in Youth and Young Adults with AML | Erin Feliciano, MD | #ASH24

AML: New Strategies For Preventing Graft vs Host Disease | Giorgia Battipaglia, MD | #ASH24

Revumenib: New Approved Drug for Relapsed/Refractory Acute Leukemia Patients | Eytan Stein, MD | #ASH24

Impact of Hospital Readmission on Quality of Life in AML | Ayobami Olafimihan, MD | #ASH24

Good Responses to Phase 2 CLIA + Ven Therapy for Acute Myeloid Leukemia | Tapan Kadia, MD | #ASH24

Menin Inhibitor Study Results: Ziftomenib for Newly Diagnosed AML Patients | Amer Zeidan, MBBS | #ASH24

VEN + IVO + AZA Combination Therapy in IDH1-Mutated AML, MDS & MPNs | Jennifer Marvin Peek, MD | #ASH24

Adding a FLT3 Inhibitor May Improve Chemo Efficacy for Newly Diagnosed AML | Musa Yilmaz, MD | #ASH24

A Unique BTK Inhibitor, Pirtobrutinib for Patients with Pretreated CLL | Jeff Sharman, MD | #ASH24

Duvelisib + Venetoclax: A Time-Limited, All Oral Option for CLL | Jennifer Crombie, MD | #ASH24